Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study

OBJECTIVES: Regorafenib improved overall survival in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies in two randomised, phase III trials, but has not been evaluated in Turkey. REGARD evaluated the safety and efficacy of regorafenib in Turkish patients with treatmen...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:BMJ Open
Hoofdauteurs: Dane, Faysal, Ozgurdal, Kirhan, Yalçın, Şuayib, Benekli, Mustafa, Aykan, Nuri Faruk, Yücel, İdris, Özkan, Metin, Evrensel, Turkkan, Sevinç, Alper, Coskun, Hasan Şenol, Sanli, Ulus Ali, Kara, Ismail Oguz, Yumuk, Perran Fulden
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BMJ Publishing Group 2020
Onderwerpen:
Oncology
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7170555/
https://ncbi.nlm.nih.gov/pubmed/32220908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2018-027665
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items